Clinical Trial Update: Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer [Phase 2, Phase 3]

View source ↗

Summary

An update on a Phase 2/3 trial evaluating whether adding bevacizumab or lapatinib to chemotherapy improves outcomes in operable esophagogastric cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophagogastric Cancer

Drugs mentioned

• Avastin (bevacizumab)
• Tykerb (lapatinib)

Snippet

Sponsor: Professor David Cunningham | Conditions: Oesophagogastric Cancer | Phase 2, Phase 3 | Status: UNKNOWN